Osteopenia Treatment Guidelines

Patient Assessment and Risk Factors

The American College of Physicians recommends that patients with osteopenia and significant bone loss, like a 72-year-old female patient, should be considered for bisphosphonate therapy due to increased risk of fracture 1, 2
A patient's age, such as 72 years old, is a significant risk factor for osteoporotic fractures, according to the American College of Internal Medicine 3, 1
Significant bone loss, indicated by a decrease in BMD, is an independent risk factor for fracture, as stated by the American College of Radiology 4

The American College of Internal Medicine recommends oral bisphosphonates, such as alendronate or risedronate, as first-line therapy for patients with osteopenia who are at increased risk for fracture due to age, significant bone loss, and degraded bone microarchitecture 1, 5
Bisphosphonates have demonstrated efficacy in reducing fracture risk in postmenopausal women with osteopenia, particularly those over 65 years of age, according to the American College of Internal Medicine 2
Generic formulations of bisphosphonates should be prescribed when possible to minimize cost, as recommended by the American College of Internal Medicine 2

The American College of Internal Medicine recommends ensuring adequate calcium intake (1000-1200 mg daily) and vitamin D supplementation (800-1000 IU daily) for patients with osteopenia 2
Weight-bearing and resistance exercises are recommended to improve bone strength and reduce fall risk, as stated by Praxis Medical Insights, but a more reliable source, the American College of Sports Medicine, also supports this recommendation, however, this is not cited in the article, an alternative is 6
Fall prevention strategies, including home safety assessment and balance training, are recommended by the American College of Internal Medicine 2

The American College of Physicians recommends against bone density monitoring during the 5-year pharmacologic treatment period, and instead suggests clinical assessment for treatment adherence, side effects, and new fractures should be performed annually 7, 5, 2
Treatment duration for bisphosphonates should typically be 5 years, after which a reassessment should be performed to determine whether to continue therapy or implement a drug holiday, as recommended by the American College of Internal Medicine 7, 2

Clinicians should take an individualized approach to starting bisphosphonate treatment in women over age 65 with osteopenia, basing the decision on the patient's baseline fracture risk assessment 8

After 5 years of treatment, clinicians should consider stopping bisphosphonate treatment unless the patient has a strong indication for continuation 9
For patients who have contraindications to bisphosphonates, denosumab may be considered as a second-line treatment option 9
For patients with very high fracture risk, anabolic agents like teriparatide or romosozumab may be considered 9

Bisphosphonates are associated with higher risk for osteonecrosis of the jaw and atypical femoral fractures in observational studies, with higher risk after longer treatment duration 9